AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push
Published . Updated .
The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but doesn’t hand the pharmaceutical company any ownership rights.
Directly affected
- AZN Astrazeneca
Named in this report.
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but doesn’t hand the pharmaceutical company any ownership rights.
Source: BioPharma Dive
How far Astrazeneca (AZN) has moved since 29 Sep 2026
Since the first closing price after “AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push,” Astrazeneca (AZN) is +1.56%. The S&P 500 fund (SPY) is +0.56% over the same days, a +1.00% difference versus the market.
Who reported a Astrazeneca (AZN) trade near this story
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). The transaction date is the publication date. The filing is listed beside the story “AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 18 days before publication, inside 30 days. The filing is listed beside the story “AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 57 days before publication, inside 60 days. The filing is listed beside the story “AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Astrazeneca (AZN)
Companies tied to this story
- AZN Astrazeneca
For “AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push,” Astrazeneca (AZN) is linked, with no stored direction, high confidence. Reason on file: The reported development directly names ASTRAZENECA PLC in the headline; GA resolved that company to AZN
- ACHC Acadia Healthcare
For “AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
For “AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
In “AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
For “AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
For “AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
For “AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push,” GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Astrazeneca (AZN)
The 29 Sep 2026 story “AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push” names Astrazeneca (AZN) because of this story.
What ties Astrazeneca (AZN) to the headline is this: The reported development directly names ASTRAZENECA PLC in the headline; GA resolved that company to AZN
A second company, Acadia Healthcare (ACHC), is listed for a different reason: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates in the story, and the Astrazeneca (AZN) price range
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. AZN traded between 154.83 and 169.73 across 20 sessions. The latest close on file is 164.02.
How strong the case is around Astrazeneca (AZN)
46 out of 100
“AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.